Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
- 14 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (14), 5931-5941
- https://doi.org/10.1158/0008-5472.can-10-0694
Abstract
Elevated Src family kinase (SFK) activity is associated with tumor invasion and metastasis. The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking. Saracatinib is likely to be used clinically in combination regimens, specifically with 5-fluorouracil (5-FU) and oxaliplatin, in CRC. The aim of this study was to determine the effect of saracatinib on oxaliplatin and 5-FU efficacy in CRC cells. Saracatinib did not modulate 5-FU efficacy but antagonized oxaliplatin in a schedule-specific manner through reduced oxaliplatin uptake via an SFK-independent mechanism. Saracatinib resembles the pharmacophore of known organic cation transporter (OCT) inhibitors and reduced oxaliplatin efficacy maximally in cells overexpressing OCT2. These data suggest that oxaliplatin uptake in CRC is attenuated by saracatinib via inhibition of OCT2, a potential consideration for the clinical development of this SFK inhibitor. Cancer Res; 70(14); 5931–41. ©2010 AACR.Keywords
Other Versions
This publication has 42 references indexed in Scilit:
- Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)British Journal of Pharmacology, 2010
- Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic DrugsMolecular Cancer Research, 2009
- Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative StressCancer Research, 2009
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemiaBlood, 2008
- Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cellsMolecular Cancer Therapeutics, 2008
- Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transportersMolecular Cancer Therapeutics, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2Cell, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2006
- Organic Cation Transporters Are Determinants of Oxaliplatin CytotoxicityCancer Research, 2006